Skip to main content
Mark Roschewski, MD, Hematology, Germantown, MD

MarkJasonRoschewskiMD

Hematology • Germantown, MD

Hematologic Oncology

Staff Clinician National Cancer Institute

Join to view full profile

Dr. Roschewski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Roschewski's full profile

Already have an account?

Education & Training

  • National Capital Consortium
    National Capital ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Dwight David Eisenhower Army Medical Center
    Dwight David Eisenhower Army Medical CenterResidency, Internal Medicine, 2001 - 2004
  • University of Nebraska College of Medicine
    University of Nebraska College of MedicineClass of 2001

Certifications & Licensure

  • NE State Medical License
    NE State Medical License 2006 - 2024
  • SD State Medical License
    SD State Medical License 1900 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • End-of-Treatment and Serial PET Imaging Has Prognostic Value and Clinical Utility in Primary Mediastinal B-cell Lymphoma Following Dose-Adjusted EPOCH-R - Response to ...  
    Mark Roschewski, Wyndham H Wilson, Christopher Melani, Haematologica

Abstracts/Posters

  • Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR
    Mark Roschewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas
    Mark Roschewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...
    Mark Roschewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • No Maintenance Required: Arguing in Favor of Observation after Frontline Therapy in Follicular... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
  • Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • CAR T-cell Win Streak Stopped by Negative Trial in Aggressive LBCL
    CAR T-cell Win Streak Stopped by Negative Trial in Aggressive LBCLDecember 14th, 2021
  • BTK Inhibition May Counter Hyperinflammatory Response Associated with Severe COVID-19
    BTK Inhibition May Counter Hyperinflammatory Response Associated with Severe COVID-19July 28th, 2020
  • New EPOCH for Adult Patients with Burkitt Lymphoma
    New EPOCH for Adult Patients with Burkitt LymphomaJune 17th, 2020
  • Join now to see all

Dr. Mark Roschewski, Dr. Mark Roschewski, MD, Dr. M Roschewski, Dr. Mark Jason Roschewski